ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.283,62
0,20%
S&P 500
5.297,10
-0,21%
US Dollar vs BRL
5,14082
0,21%
Bitcoin
65.261,33
0,03%
Brent Oil
83,145
-0,07%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Novan Inc (NOVN)

  7. Novan Inc (NOVN) Notícias

NOVN

Novan (NOVN)

Novan Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NOVN
DataHoraFonteTítuloCódigoCompanhia
02/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
01/05/202412:49Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
25/03/202409:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
05/01/202411:23GlobeNewswire Inc.Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisNASDAQ:NOVNNovan Inc
10/12/202321:30GlobeNewswire Inc.Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NASDAQ:NOVNNovan Inc
08/12/202311:15GlobeNewswire Inc.Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsNASDAQ:NOVNNovan Inc
05/12/202321:16GlobeNewswire Inc.Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNASDAQ:NOVNNovan Inc
20/11/202303:15GlobeNewswire Inc.Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHNASDAQ:NOVNNovan Inc
17/07/202309:45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:NOVNNovan Inc
27/06/202319:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NOVNNovan Inc
16/06/202318:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
05/06/202310:00GlobeNewswire Inc.Novan to Provide Corporate Update at its 2023 Annual Meeting of StockholdersNASDAQ:NOVNNovan Inc
31/05/202317:05GlobeNewswire Inc.Novan Focuses Strategic Direction and Announces RestructuringNASDAQ:NOVNNovan Inc
15/05/202307:56Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NOVNNovan Inc
15/05/202307:45GlobeNewswire Inc.Novan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NOVNNovan Inc
08/05/202310:05GlobeNewswire Inc.Novan to Report First Quarter 2023 Financial Results on May 15, 2023NASDAQ:NOVNNovan Inc
27/04/202310:10GlobeNewswire Inc.Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹NASDAQ:NOVNNovan Inc
27/04/202310:00Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NOVNNovan Inc
20/04/202310:00GlobeNewswire Inc.Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDNASDAQ:NOVNNovan Inc
30/03/202307:30GlobeNewswire Inc.Novan Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:NOVNNovan Inc
23/03/202310:00GlobeNewswire Inc.Novan to Report Full Year 2022 Financial Results on March 30, 2023NASDAQ:NOVNNovan Inc
20/03/202310:38Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NOVNNovan Inc
19/03/202320:00GlobeNewswire Inc.Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onsetNASDAQ:NOVNNovan Inc
16/03/202319:47GlobeNewswire Inc.Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancerNASDAQ:NOVNNovan Inc
16/03/202317:15GlobeNewswire Inc.Novan Announces Closing of $6.0 Million Registered Direct OfferingNASDAQ:NOVNNovan Inc
14/03/202309:30GlobeNewswire Inc.Novan to Present at the Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:NOVNNovan Inc
14/03/202309:00GlobeNewswire Inc.Novan Announces $6.0 Million Registered Direct OfferingNASDAQ:NOVNNovan Inc
08/03/202311:00GlobeNewswire Inc.Novan Moves Forward with Unified Corporate BrandingNASDAQ:NOVNNovan Inc
07/03/202310:00GlobeNewswire Inc.FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024NASDAQ:NOVNNovan Inc
18/01/202310:05GlobeNewswire Inc.Novan to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:NOVNNovan Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NOVN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HBOR3
HELBOR ON
BOV
BRSR6
BANRISUL PNB
BOV
GFSA3
GAFISA ON
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados